Charles River Laboratorie (CRL) Misses Q2 EPS by 1c; Extends Agreement with AstraZeneca (AZN)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Charles River Laboratories and AstraZeneca Renew Strategic Partnership Agreement
July 30, 2015 7:01 AM EDT- Leading Global CRO and Global Biopharmaceutical Company Extend Relationship to Accelerate Drug Development -
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has extended its initial three-year partnership with AstraZeneca (NYSE: AZN) for an additional five-year period. Under the agreement, which extends into 2020, Charles River retains its position as AstraZenecas preferred strategic partner for outsourced regulated safety assessment and development DMPK (drug metabolism and pharmacokinetics).
James C. Foster, Chairman,... More
Charles River Laboratories Announces Second-Quarter 2015 Results from Continuing Operations
July 30, 2015 7:00 AM EDTSecond-Quarter Revenue of $339.6 Million
Second-Quarter GAAP Earnings per Share of $1.02
and
Non-GAAP Earnings per Share of $0.96
Updates 2015 Guidance for Celsis Acquisition
Renews Strategic Partnership with AstraZeneca
Plans to Reopen Shrewsbury, Massachusetts Facility in Early 2016
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter of 2015. For the quarter, revenue from continuing operations was $339.6 million, a decrease of 0.5% from $341.2 million in the second quarter of 2014. Foreign currency... More
